MapLight Therapeutics (MPLT) Profit After Tax (2024 - 2025)
MapLight Therapeutics' (MPLT) quarterly Profit After Tax came in at -$79.5 million in Q4 2025, down 274.71% year-on-year from $45.5 million in Q4 2024, and down 170.41% quarter-over-quarter from -$29.4 million in Q3 2025.
MapLight Therapeutics (MPLT) Profit After Tax (2024 - 2025) Analysis & Trends
MapLight Therapeutics has disclosed Profit After Tax across 2 years of filings, most recently posting -$79.5 million for Q4 2025.
- Profit After Tax for Q4 2025 came in at -$79.5 million, down 274.71% year-over-year; the trailing twelve-month figure through Dec 2025 was -$149.2 million (changed N/A YoY), and the FY2025 annual result was -$161.2 million, down 107.72% from the prior year.
- Profit After Tax came in at -$79.5 million for Q4 2025 at MapLight Therapeutics, down from -$29.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$19.0 million in Q3 2024 to a low of -$79.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | MapLight Therapeutics | 248.88 Mn | 248.88 Mn | - | -79.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79.55 Mn |
| Sep 30, 2025 | -29.42 Mn |
| Dec 31, 2024 | -21.23 Mn |
| Sep 30, 2024 | -19.02 Mn |